Sage Therapeutics (SAGE, Financial) reported a significant drop in its stock price, falling more than 30% in pre-market trading. It later stabilized at an 11% decline. This drop followed the announcement that their Alzheimer's treatment drug, dalzanemdor (SAGE-718), failed to meet primary endpoints in a mid-stage trial. The phase two LIGHTWAVE trial involved 174 participants diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's disease. The trial aimed to measure the disease's impact ...